Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.46 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 2/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.42 |
| ▸ | PNMT | P11086 | 4/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30199461 | 1.00 | HRH3 (0.46) | HRH3CD274SYKADRA2AADRA2B | |
| SCHEMBL30199561 | 0.85 | SYK (0.56) | HRH3CD274SYKADRA2AADRA2B | |
| SCHEMBL29098117 | 0.85 | SYK (0.56) | HRH3CD274SYKADRA2AADRA2B | |
| SCHEMBL30198781 | 0.78 | HRH3 (0.46) | HRH3CD274ADRA2AADRA2BADRA2C | |
| SCHEMBL29097881 | 0.78 | HRH3 (0.46) | HRH3CD274ADRA2AADRA2BADRA2C | |
| SCHEMBL30199543 | 0.76 | HRH3 (0.50) | HRH3CD274ADRA2AADRA2BADRA2C | |
| SCHEMBL29097817 | 0.76 | HRH3 (0.50) | HRH3CD274ADRA2AADRA2BADRA2C | |
| SCHEMBL29474892 | 0.76 | HRH3 (0.59) | HRH3CD274PNMT | |
| SCHEMBL3503754 | 0.76 | HRH3 (0.59) | HRH3CD274PNMT | |
| SCHEMBL23537837 | 0.75 | HRH3 (0.46) | HRH3CD274SYKADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115594669-A | Fused ring derivative and preparation method and medical application thereof | 深圳信立泰药业股份有限公司（CN） | 2023-01-13 | — | — | CN | disclosed |